| scholarly article | Q13442814 |
| P50 | author | Wolf-Dieter Heiss | Q8029775 |
| J Kessler | Q67216136 | ||
| Karl Herholz | Q67216139 | ||
| P2093 | author name string | B. Szelies | |
| P2860 | cites work | Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 |
| Therapeutic strategies in Alzheimer's disease | Q37578886 | ||
| Study of Cerebral Function with Positron Computed Tomography | Q40112665 | ||
| Neocortical metabolic abnormalities precede nonmemory cognitive defects in early Alzheimer's-type dementia | Q48305999 | ||
| Positron emission tomography in Alzheimer's disease | Q48328045 | ||
| Regional kinetic constants and cerebral metabolic rate for glucose in normal human volunteers determined by dynamic positron emission tomography of [18F]-2-fluoro-2-deoxy-D-glucose | Q48661699 | ||
| The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia | Q48719942 | ||
| Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose | Q48768629 | ||
| Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity | Q48983820 | ||
| Effect of piracetam on cerebral glucose metabolism in Alzheimer's disease as measured by positron emission tomography. | Q53304428 | ||
| [Cerebral glucose metabolism in presenile dementia of the Alzheimer type--follow-up of therapy with muscarinergic choline agonists] | Q53305416 | ||
| The Global Deterioration Scale for assessment of primary degenerative dementia | Q57279034 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| emission computed tomography | Q5372630 | ||
| history and philosophy of science | Q5774812 | ||
| P1104 | number of pages | 7 | |
| P304 | page(s) | 65-71 | |
| P577 | publication date | 1991-01-01 | |
| P1433 | published in | Annals of the New York Academy of Sciences | Q2431664 |
| P1476 | title | Abnormalities of Energy Metabolism in Alzheimer's Disease Studied with PETa | |
| P478 | volume | 640 |
| Q36868699 | A mitochondrial bottleneck hypothesis of Alzheimer's disease |
| Q36640367 | A non-transgenic mouse model (icv-STZ mouse) of Alzheimer's disease: similarities to and differences from the transgenic model (3xTg-AD mouse). |
| Q36404535 | Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood-Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease. |
| Q39398227 | Alzheimer's disease and metabolic syndrome: A link from oxidative stress and inflammation to neurodegeneration. |
| Q34646469 | Ammonia and Alzheimer's disease |
| Q34007682 | Analysis of microdissected neurons by 18O mass spectrometry reveals altered protein expression in Alzheimer's disease |
| Q52022485 | Assessment of dopamine metabolism in brain of patients with dementia by means of 18F-fluorodopa and PET. |
| Q31108663 | Brain gene expression of a sporadic (icv-STZ Mouse) and a familial mouse model (3xTg-AD mouse) of Alzheimer's disease |
| Q34305448 | Cerebral blood flow and metabolic abnormalities in Alzheimer's disease |
| Q33855135 | Cerebral glucose metabolism on positron emission tomography of children |
| Q44266127 | Clinical impact of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of brain diseases |
| Q34061233 | Cognition, glucose metabolism and amyloid burden in Alzheimer's disease |
| Q48566884 | Cytochrome oxidase in Alzheimer's disease: biochemical, histochemical, and immunohistochemical analyses of the visual and other systems |
| Q44245798 | Deleterious network hypothesis of Alzheimer's disease |
| Q58553621 | Direct Crosstalk Between -GlcNAcylation and Phosphorylation of Tau Protein Investigated by NMR Spectroscopy |
| Q53288040 | Direct comparison study between FDG-PET and IMP-SPECT for diagnosing Alzheimer's disease using 3D-SSP analysis in the same patients. |
| Q48178864 | Discrimination between patients with mild Alzheimer's disease and healthy subjects based on cerebral blood flow images of the lateral views in xenon-enhanced computed tomography |
| Q27009399 | Functional O-GlcNAc modifications: implications in molecular regulation and pathophysiology |
| Q38779434 | Hypoxia-inducible factors as neuroprotective agent in Alzheimer's disease. |
| Q31110945 | Imaging biomarkers and their role in dementia clinical trials |
| Q34073596 | Increased O-GlcNAc levels correlate with decreased O-GlcNAcase levels in Alzheimer disease brain |
| Q53434499 | Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. |
| Q47740742 | Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice |
| Q30573779 | Intracerebroventricular streptozotocin exacerbates Alzheimer-like changes of 3xTg-AD mice |
| Q40900244 | Is ammonia a pathogenetic factor in Alzheimer's disease? |
| Q37833589 | Lectin-affinity chromatography brain glycoproteomics and Alzheimer disease: insights into protein alterations consistent with the pathology and progression of this dementing disorder |
| Q34515333 | Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice. |
| Q24656640 | Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease |
| Q26864926 | Reevaluating Metabolism in Alzheimer's Disease from the Perspective of the Astrocyte-Neuron Lactate Shuttle Model |
| Q41114461 | The current status of clinical PET imaging |
| Q38064315 | The role of glucose transporters in brain disease: diabetes and Alzheimer’s Disease |
| Q53203529 | Transferrin receptors in the normal human hippocampus and in Alzheimer's disease. |
| Q48645083 | Unilateral injection of Aβ25-35 in the hippocampus reduces the number of dendritic spines in hyperglycemic rats |
| Q40660449 | What is primary and what secondary for amyloid deposition in Alzheimer's disease |
Search more.